# Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

> **NCT04558931** · PHASE2 · RECRUITING · sponsor: **Karolinska Institutet** · enrollment: 62 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CellProtect
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT04558931
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-02
- **Primary completion:** 2027-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04558931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04558931, "Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04558931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*